ChinaBio^® Partnering Forum 2012 Press Releases

May 14, 2012Partnering Bootcamp Kicks Off ChinaBio^® Partnering Forum 2012 In SuzhouInaugural pre-conference program promotes dealmaking
EBD Group, the leading partnering firm for the life science industry, and ChinaBio^® LLC, a leading consulting firm in Shanghai, will host ChinaBio^® Partnering Forum 2012 at the Kempinski Hotel Suzhou, May 23–24 in Suzhou, China. A special Partnering Bootcamp, a half-day pre-conference program sponsored by Cooley LLP, will be held on Tuesday, May 22 prior to th...more ►

May 7, 2012ChinaBio^® Partnering Forum 2012 In Suzhou Brings Big Pharma Companies to ChinaConference program features panels and a fireside chat with top-name executives
The international biotech and pharma community will converge upon the city of Suzhou, China, a rapidly growing base for life science industries, at ChinaBio^® Partnering Forum 2012 at the Kempinski Hotel Suzhou, May 23–24. Co-organizers EBD Group, the leading partnering firm for the life science industry, and ChinaBio^® LLC, a leading consulting firm in Shangh...more ►

February 15, 2012ChinaBio^® Partnering Forum 2012 to be held In Suzhou, China"Venice of the East" will host global life science event
The international biotech and pharma community will converge upon the city of Suzhou, China, a rapidly growing base for life science industries, at ChinaBio^® Partnering Forum 2012 at the Kempinski Hotel Suzhou, May 23–24. The fourth annual conference is the premier life science partnering event in China, and is expected to bring hundreds of attendees from around the world se...more ►

1 May 2012 Epizyme: Intensive dealmaking in pursuit of personalized therapeutics Little was known about the branch of epigenetics called histone methyltransferases (HMTs) when Epizyme began in late 2007. Yet before the company presented the world's first animal demonstration of efficacy for HMTs in July 2011, it had already attracted USD 54 million in venture investment and USD 45 million in funding from two pharma partners and two foundations. more ►

1 May 2012 Forma Therapeutics: Structured acquisitions to fix broken biotech model In January this year, Forma Therapeutics announced two conventional agreements for assets spinning out of its innovative discovery platform that aim for high-risk targets but hold high-reward valuations, potentially totaling USD 1.45 billion in milestone payments. more ►

1 May 2012 Foundation Medicine: Molecular information disrupting the oncology universe The news from Foundation Medicine could not be more encouraging for the company, nor more disruptive for the universe of oncology as we know it today. more ►

1 May 2012 Joslin Diabetes Center: Building “collaboratories” for diabetes solutions John Brooks has lit a fire under the Joslin Diabetes Center. Over the past year a string of announcements has flowed from the traditionally understated 114-year-old institution. more ►

20 April 2012 EU medtech management and oversight: New, but complex, proposals A clear, transparent, single mechanism for the oversight and coordination of medtech rules is needed to restore confidence in the European medtech regulatory system which has been badly undermined by recent product safety scandals. more ►